Versartis Inc. (NASDAQ:VSAR)’s share price traded up 3.7% during mid-day trading on Thursday . The company traded as high as $11.72 and last traded at $11.35, with a volume of 79,249 shares trading hands. The stock had previously closed at $10.95.

A number of equities analysts have issued reports on the company. Zacks Investment Research downgraded Versartis from a “hold” rating to a “sell” rating in a research note on Wednesday, June 8th. Morgan Stanley reiterated a “hold” rating on shares of Versartis in a research note on Saturday, April 30th. Northland Securities assumed coverage on Versartis in a research note on Thursday, April 7th. They set an “outperform” rating for the company. Finally, Canaccord Genuity reiterated a “buy” rating on shares of Versartis in a research note on Monday, April 4th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $17.20.

The firm’s market capitalization is $329.01 million. The stock’s 50-day moving average price is $10.79 and its 200 day moving average price is $9.31.

Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is engaged in developing long-acting recombinant human growth hormone (rhGH), somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s product pipeline includes VRS-317 and XTEN Technology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.